Literature DB >> 24363521

Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders.

Srinevas K Reddy1, Min Zhan1, H Richard Alexander1, Samer S El-Kamary1.   

Abstract

AIM: To explore associations between nonalcoholic fatty liver disease (NAFLD) and benign gastrointestinal and pancreato-biliary disorders.
METHODS: Patient demographics, diagnoses, and hospital outcomes from the 2010 Nationwide Inpatient Sample were analyzed. Chronic liver diseases were identified using International Classification of Diseases, the 9(th) Revision, Clinical Modification codes. Patients with NAFLD were compared to those with other chronic liver diseases for the endpoints of total hospital charges, disease severity, and hospital mortality. Multivariable stepwise logistic regression analyses to assess for the independent association of demographic, comorbidity, and diagnosis variables with the event of NAFLD (vs other chronic liver diseases) were also performed.
RESULTS: Of 7800441 discharge records, 32347 (0.4%) and 271049 (3.5%) included diagnoses of NAFLD and other chronic liver diseases, respectively. NAFLD patients were younger (average 52.3 years vs 55.3 years), more often female (58.8% vs 41.6%), less often black (9.6% vs 18.6%), and were from higher income areas (23.7% vs 17.7%) compared to counterparts with other chronic liver diseases (all P < 0.0001). Diabetes mellitus (43.4% vs 28.9%), hypertension (56.9% vs 47.6%), morbid obesity (36.9% vs 8.0%), dyslipidemia (37.9% vs 15.6%), and the metabolic syndrome (28.75% vs 8.8%) were all more common among NAFLD patients (all P < 0.0001). The average total hospital charge ($39607 vs $51665), disease severity scores, and intra-hospital mortality (0.9% vs 6.0%) were lower among NALFD patients compared to those with other chronic liver diseases (all P < 0.0001).Compared with other chronic liver diseases, NAFLD was significantly associated with diverticular disorders [OR = 4.26 (3.89-4.67)], inflammatory bowel diseases [OR = 3.64 (3.10-4.28)], gallstone related diseases [OR = 3.59 (3.40-3.79)], and benign pancreatitis [OR = 2.95 (2.79-3.12)] on multivariable logistic regression (all P < 0.0001) when the latter disorders were the principal diagnoses on hospital discharge. Similar relationships were observed when the latter disorders were associated diagnoses on hospital discharge.
CONCLUSION: NAFLD is associated with diverticular, inflammatory bowel, gallstone, and benign pancreatitis disorders. Compared with other liver diseases, patients with NAFLD have lower hospital charges and mortality.
© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.

Entities:  

Keywords:  Chronic liver disease; Diverticular disease; Gallstones; Inflammatory bowel disease; Nationwide inpatient sample; Nonalcoholic fatty liver disease; Pancreatitis

Mesh:

Year:  2013        PMID: 24363521      PMCID: PMC3857453          DOI: 10.3748/wjg.v19.i45.8301

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  32 in total

1.  Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.

Authors:  Brent A Neuschwander-Tetri; Jeanne M Clark; Nathan M Bass; Mark L Van Natta; Aynur Unalp-Arida; James Tonascia; Claudia O Zein; Elizabeth M Brunt; David E Kleiner; Arthur J McCullough; Arun J Sanyal; Anna Mae Diehl; Joel E Lavine; Naga Chalasani; Kris V Kowdley
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

2.  High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism.

Authors:  Matteo Nicola Dario Di Minno; Antonella Tufano; Anna Rusolillo; Giovanni Di Minno; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2010-12-28       Impact factor: 5.742

3.  Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice.

Authors:  Marc-Emmanuel Dumas; Richard H Barton; Ayo Toye; Olivier Cloarec; Christine Blancher; Alice Rothwell; Jane Fearnside; Roger Tatoud; Véronique Blanc; John C Lindon; Steve C Mitchell; Elaine Holmes; Mark I McCarthy; James Scott; Dominique Gauguier; Jeremy K Nicholson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-08       Impact factor: 11.205

4.  Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis.

Authors:  Rohit Loomba; Maria Abraham; Aynur Unalp; Laura Wilson; Joel Lavine; Ed Doo; Nathan M Bass
Journal:  Hepatology       Date:  2012-07-26       Impact factor: 17.425

5.  Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.

Authors:  Nathalie C Leite; Cristiane A Villela-Nogueira; Vera L N Pannain; Adriana C Bottino; Guilherme F M Rezende; Claudia R L Cardoso; Gil F Salles
Journal:  Liver Int       Date:  2011-02-20       Impact factor: 5.828

6.  Non-alcoholic steatohepatitis associated with small intestinal diverticulosis and bacterial overgrowth.

Authors:  M Nazim; G Stamp; H J Hodgson
Journal:  Hepatogastroenterology       Date:  1989-10

7.  High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis.

Authors:  Jean-Marc Sabaté; Pauline Jouët; Florence Harnois; Charlotte Mechler; Simon Msika; Maggy Grossin; Benoît Coffin
Journal:  Obes Surg       Date:  2008-02-20       Impact factor: 4.129

8.  Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C.

Authors:  Jason M Hui; James G Kench; Shivakumar Chitturi; Archana Sud; Geoffrey C Farrell; Karen Byth; Pauline Hall; Mahbub Khan; Jacob George
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

9.  Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease.

Authors:  Elizabeth M Brunt; Sunil Ramrakhiani; Barry G Cordes; Brent A Neuschwander-Tetri; Christine G Janney; Bruce R Bacon; Adrian M Di Bisceglie
Journal:  Mod Pathol       Date:  2003-01       Impact factor: 7.842

10.  Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort.

Authors:  Matthew J Armstrong; Diarmaid D Houlihan; Louise Bentham; Jean C Shaw; Robert Cramb; Simon Olliff; Paramjit S Gill; James M Neuberger; Richard J Lilford; Philip N Newsome
Journal:  J Hepatol       Date:  2011-05-18       Impact factor: 25.083

View more
  15 in total

1.  Atrial fibrillation is highly prevalent yet undertreated in patients with biopsy-proven nonalcoholic steatohepatitis.

Authors:  Maureen Whitsett; Jane Wilcox; Amy Yang; Lihui Zhao; Mary Rinella; Lisa B VanWagner
Journal:  Liver Int       Date:  2018-12-21       Impact factor: 5.828

2.  PM2.5 air pollution exposure and nonalcoholic fatty liver disease in the Nationwide Inpatient Sample.

Authors:  Trang VoPham; Nicole J Kim; Kristin Berry; Jason A Mendoza; Joel D Kaufman; George N Ioannou
Journal:  Environ Res       Date:  2022-06-07       Impact factor: 8.431

Review 3.  Predicting Severity of Acute Pancreatitis.

Authors:  Dong Wook Lee; Chang Min Cho
Journal:  Medicina (Kaunas)       Date:  2022-06-11       Impact factor: 2.948

Review 4.  Significant Association Between Gallstone Disease and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.

Authors:  Veeravich Jaruvongvanich; Anawin Sanguankeo; Sikarin Upala
Journal:  Dig Dis Sci       Date:  2016-03-18       Impact factor: 3.199

5.  Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis.

Authors:  Nicole E Rich; Stefany Oji; Arjmand R Mufti; Jeffrey D Browning; Neehar D Parikh; Mobolaji Odewole; Helen Mayo; Amit G Singal
Journal:  Clin Gastroenterol Hepatol       Date:  2017-09-29       Impact factor: 11.382

Review 6.  Multifactorial Scores and Biomarkers of Prognosis of Acute Pancreatitis: Applications to Research and Practice.

Authors:  Pedro Silva-Vaz; Ana Margarida Abrantes; Miguel Castelo-Branco; António Gouveia; Maria Filomena Botelho; José Guilherme Tralhão
Journal:  Int J Mol Sci       Date:  2020-01-04       Impact factor: 5.923

7.  Safety and Effectiveness of Essential Phospholipids Paste in Patients with Non-alcoholic Fatty Liver Disease or Viral Hepatitis.

Authors:  Vladimir T Ivashkin; Igor V Maev; Chavdar S Pavlov; Marina V Mayevskaya; Aleksey A Samsonov; Lyudmila K Palgova; Kirill M Starostin
Journal:  Turk J Gastroenterol       Date:  2021-09       Impact factor: 1.555

8.  Impact of Fatty Liver on Acute Pancreatitis Severity.

Authors:  Seung Bae Yoon; In Seok Lee; Moon Hyung Choi; Kyungjin Lee; Hyoju Ham; Hyun Jin Oh; Se Hwan Park; Chul-Hyun Lim; Myung-Gyu Choi
Journal:  Gastroenterol Res Pract       Date:  2017-04-27       Impact factor: 2.260

9.  Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability.

Authors:  Jay Luther; John J Garber; Hamed Khalili; Maneesh Dave; Shyam Sundhar Bale; Rohit Jindal; Daniel L Motola; Sanjana Luther; Stefan Bohr; Soung Won Jeoung; Vikram Deshpande; Gurminder Singh; Jerrold R Turner; Martin L Yarmush; Raymond T Chung; Suraj J Patel
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2015-03

10.  Influence of Fatty Liver on the Severity and Clinical Outcome in Acute Pancreatitis.

Authors:  Chunfang Xu; Zhenguo Qiao; Yongda Lu; Deqing Zhang; Zhenyu Jia; Xiaohui Zhuang; Yuqi Shi; Ting Xu; Lihua Xing; Jiaqing Shen
Journal:  PLoS One       Date:  2015-11-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.